Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

Abroad (travel likely)RecruitingPHASE2

Conditions

Diffuse Large B-Cell Lymphoma-Recurrent · Diffuse Large B-Cell Lymphoma-Refractory

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Zhang Huilai, PHD) · zhlwgq@126.com · 086-02223340123

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

Diffuse Large B-cell Lymphoma · Relapsed and Refractory

Abroad (travel likely)RecruitingPHASE2

Xiamen, China

Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma

DIFFUSE LARGE B-CELL LYMPHOMA

Abroad (travel likely)RecruitingPHASE2

A Coruña, Spain · Palma de Mallorca, Spain

A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

Large B-cell Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Nanning, China · Zhengzhou, China

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Non-Hodgkin Lymphoma · Burkitt Lymphoma · Diffuse Large B-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Valhalla, United States